Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker

Lahong Zhang, Zhaojun Chen, Dan Xue, Qi Zhang, Xiyong Liu, Frank Luh, Liquan Hong, Hang Zhang, Feng Pan, Yuhua Liu, Peiguo Chu, Shu Zheng, Guoqiang Lou, Yun Yen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Mitochondrial serine hydroxylmethyltransferase 2 (SHMT2) is a key enzyme in the serine/glycine synthesis pathway. SHMT2 has been implicated as a critical component for tumor cell survival. The aim of the present study was to evaluate the prognostic value and efficiency of SHMT2 as a biomarker in patients with breast cancer. Individual and pooled survival analyses were performed on five independent breast cancer microarray datasets. Gene signatures enriched by SHMT2 were also analyzed in these datasets. SHMT2 protein expression was detected using immunohistochemistry (IHC) assay in 128 breast cancer cases. Gene set enrichment analysis revealed that SHMT2 was significantly associated with gene signatures of mitochondrial module, cancer invasion, metastasis and poor survival among breast cancer patients (p<0.05). The clinical relevance of SHMT2 was validated on IHC data. The mitochondrial localization of SHMT2 protein was visualized on IHC staining. Independent and pooled analysis confirmed that SHMT2 expression was associated with breast cancer tumor aggressiveness (TNM staging and Elson grade) in a dose-dependent manner (p<0.05). The prognostic performance of SHMT2 mRNA was comparable to other gene signatures and proved superior to TNM staging. Further analysis results indicated that SHMT2 had better prognostic value for estrogen receptor (ER)-negative breast cancer patients, compared to ER-positive patients. In cases involving stage IIb breast cancer, chemotherapy significantly extended survival time among patients with high SHMT2 expression. These results indicate that SHMT2 may be a valuable prognostic biomarker in ER-negative breast cancer cases. Furthermore, SHMT2 may be a potential target for breast cancer treatment and drug discovery.

Original languageEnglish
Pages (from-to)2489-2500
Number of pages12
JournalOncology Reports
Volume36
Issue number5
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Tumor Biomarkers
Hydroxyl Radical
Serine
Breast Neoplasms
Therapeutics
Estrogen Receptors
Neoplasm Staging
Immunohistochemistry
methylcobalamin-coenzyme M methyltransferase
Biomarkers
Genes
Mitochondrial Genes
Survival
Drug Discovery
Survival Analysis
Glycine
Neoplasms
Cell Survival
Proteins

Keywords

  • ER-negative breast cancer
  • Gene set enrichment analysis
  • Mitochondrial serine hydroxylmethyltransferase 2
  • Prognostic biomarker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker. / Zhang, Lahong; Chen, Zhaojun; Xue, Dan; Zhang, Qi; Liu, Xiyong; Luh, Frank; Hong, Liquan; Zhang, Hang; Pan, Feng; Liu, Yuhua; Chu, Peiguo; Zheng, Shu; Lou, Guoqiang; Yen, Yun.

In: Oncology Reports, Vol. 36, No. 5, 01.11.2016, p. 2489-2500.

Research output: Contribution to journalArticle

Zhang, L, Chen, Z, Xue, D, Zhang, Q, Liu, X, Luh, F, Hong, L, Zhang, H, Pan, F, Liu, Y, Chu, P, Zheng, S, Lou, G & Yen, Y 2016, 'Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker', Oncology Reports, vol. 36, no. 5, pp. 2489-2500. https://doi.org/10.3892/or.2016.5112
Zhang, Lahong ; Chen, Zhaojun ; Xue, Dan ; Zhang, Qi ; Liu, Xiyong ; Luh, Frank ; Hong, Liquan ; Zhang, Hang ; Pan, Feng ; Liu, Yuhua ; Chu, Peiguo ; Zheng, Shu ; Lou, Guoqiang ; Yen, Yun. / Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker. In: Oncology Reports. 2016 ; Vol. 36, No. 5. pp. 2489-2500.
@article{e5c87fecafe743a89bacdeb922b7264e,
title = "Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker",
abstract = "Mitochondrial serine hydroxylmethyltransferase 2 (SHMT2) is a key enzyme in the serine/glycine synthesis pathway. SHMT2 has been implicated as a critical component for tumor cell survival. The aim of the present study was to evaluate the prognostic value and efficiency of SHMT2 as a biomarker in patients with breast cancer. Individual and pooled survival analyses were performed on five independent breast cancer microarray datasets. Gene signatures enriched by SHMT2 were also analyzed in these datasets. SHMT2 protein expression was detected using immunohistochemistry (IHC) assay in 128 breast cancer cases. Gene set enrichment analysis revealed that SHMT2 was significantly associated with gene signatures of mitochondrial module, cancer invasion, metastasis and poor survival among breast cancer patients (p<0.05). The clinical relevance of SHMT2 was validated on IHC data. The mitochondrial localization of SHMT2 protein was visualized on IHC staining. Independent and pooled analysis confirmed that SHMT2 expression was associated with breast cancer tumor aggressiveness (TNM staging and Elson grade) in a dose-dependent manner (p<0.05). The prognostic performance of SHMT2 mRNA was comparable to other gene signatures and proved superior to TNM staging. Further analysis results indicated that SHMT2 had better prognostic value for estrogen receptor (ER)-negative breast cancer patients, compared to ER-positive patients. In cases involving stage IIb breast cancer, chemotherapy significantly extended survival time among patients with high SHMT2 expression. These results indicate that SHMT2 may be a valuable prognostic biomarker in ER-negative breast cancer cases. Furthermore, SHMT2 may be a potential target for breast cancer treatment and drug discovery.",
keywords = "ER-negative breast cancer, Gene set enrichment analysis, Mitochondrial serine hydroxylmethyltransferase 2, Prognostic biomarker",
author = "Lahong Zhang and Zhaojun Chen and Dan Xue and Qi Zhang and Xiyong Liu and Frank Luh and Liquan Hong and Hang Zhang and Feng Pan and Yuhua Liu and Peiguo Chu and Shu Zheng and Guoqiang Lou and Yun Yen",
year = "2016",
month = "11",
day = "1",
doi = "10.3892/or.2016.5112",
language = "English",
volume = "36",
pages = "2489--2500",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker

AU - Zhang, Lahong

AU - Chen, Zhaojun

AU - Xue, Dan

AU - Zhang, Qi

AU - Liu, Xiyong

AU - Luh, Frank

AU - Hong, Liquan

AU - Zhang, Hang

AU - Pan, Feng

AU - Liu, Yuhua

AU - Chu, Peiguo

AU - Zheng, Shu

AU - Lou, Guoqiang

AU - Yen, Yun

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Mitochondrial serine hydroxylmethyltransferase 2 (SHMT2) is a key enzyme in the serine/glycine synthesis pathway. SHMT2 has been implicated as a critical component for tumor cell survival. The aim of the present study was to evaluate the prognostic value and efficiency of SHMT2 as a biomarker in patients with breast cancer. Individual and pooled survival analyses were performed on five independent breast cancer microarray datasets. Gene signatures enriched by SHMT2 were also analyzed in these datasets. SHMT2 protein expression was detected using immunohistochemistry (IHC) assay in 128 breast cancer cases. Gene set enrichment analysis revealed that SHMT2 was significantly associated with gene signatures of mitochondrial module, cancer invasion, metastasis and poor survival among breast cancer patients (p<0.05). The clinical relevance of SHMT2 was validated on IHC data. The mitochondrial localization of SHMT2 protein was visualized on IHC staining. Independent and pooled analysis confirmed that SHMT2 expression was associated with breast cancer tumor aggressiveness (TNM staging and Elson grade) in a dose-dependent manner (p<0.05). The prognostic performance of SHMT2 mRNA was comparable to other gene signatures and proved superior to TNM staging. Further analysis results indicated that SHMT2 had better prognostic value for estrogen receptor (ER)-negative breast cancer patients, compared to ER-positive patients. In cases involving stage IIb breast cancer, chemotherapy significantly extended survival time among patients with high SHMT2 expression. These results indicate that SHMT2 may be a valuable prognostic biomarker in ER-negative breast cancer cases. Furthermore, SHMT2 may be a potential target for breast cancer treatment and drug discovery.

AB - Mitochondrial serine hydroxylmethyltransferase 2 (SHMT2) is a key enzyme in the serine/glycine synthesis pathway. SHMT2 has been implicated as a critical component for tumor cell survival. The aim of the present study was to evaluate the prognostic value and efficiency of SHMT2 as a biomarker in patients with breast cancer. Individual and pooled survival analyses were performed on five independent breast cancer microarray datasets. Gene signatures enriched by SHMT2 were also analyzed in these datasets. SHMT2 protein expression was detected using immunohistochemistry (IHC) assay in 128 breast cancer cases. Gene set enrichment analysis revealed that SHMT2 was significantly associated with gene signatures of mitochondrial module, cancer invasion, metastasis and poor survival among breast cancer patients (p<0.05). The clinical relevance of SHMT2 was validated on IHC data. The mitochondrial localization of SHMT2 protein was visualized on IHC staining. Independent and pooled analysis confirmed that SHMT2 expression was associated with breast cancer tumor aggressiveness (TNM staging and Elson grade) in a dose-dependent manner (p<0.05). The prognostic performance of SHMT2 mRNA was comparable to other gene signatures and proved superior to TNM staging. Further analysis results indicated that SHMT2 had better prognostic value for estrogen receptor (ER)-negative breast cancer patients, compared to ER-positive patients. In cases involving stage IIb breast cancer, chemotherapy significantly extended survival time among patients with high SHMT2 expression. These results indicate that SHMT2 may be a valuable prognostic biomarker in ER-negative breast cancer cases. Furthermore, SHMT2 may be a potential target for breast cancer treatment and drug discovery.

KW - ER-negative breast cancer

KW - Gene set enrichment analysis

KW - Mitochondrial serine hydroxylmethyltransferase 2

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=84989955303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989955303&partnerID=8YFLogxK

U2 - 10.3892/or.2016.5112

DO - 10.3892/or.2016.5112

M3 - Article

VL - 36

SP - 2489

EP - 2500

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -